Company Filing History:
Years Active: 1998-2000
Title: Immanuel Luescher: Innovator in Cancer Research
Introduction
Immanuel Luescher is a prominent inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly in the development of tumor rejection antigens. With a total of 2 patents, his work has the potential to impact diagnostic and therapeutic methodologies in oncology.
Latest Patents
Luescher's latest patents include "Tumor rejection antigens presented by HLA-B44 molecules" and "Tumor rejection antigens presented by HLA-244 molecules." These patents describe peptides that are derived from MAGE tumor rejection antigen precursors. The peptides are useful in both diagnostic and therapeutic methodologies, showcasing their importance in cancer treatment.
Career Highlights
Immanuel Luescher is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research. His work focuses on the identification and application of tumor rejection antigens, which are crucial for developing effective cancer therapies.
Collaborations
Luescher has collaborated with notable colleagues such as Jean Herman and Pierre G Coulie. These partnerships enhance the research efforts in the field of cancer immunology and contribute to the advancement of innovative treatments.
Conclusion
Immanuel Luescher's contributions to cancer research through his patents and collaborations highlight his role as an innovator in the field. His work continues to pave the way for new diagnostic and therapeutic approaches in oncology.